D-Glucose-6-phosphate Dipotassium Salt | 5996-17-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-Glucose-6-phosphate Dipotassium Salt
• CAS: 5996-17-8
• 化学式: C6H13KO9P
• 分子量: 299.23
• InChiKey: NVPNSVWJFXBIBR-BTVCFUMJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.64
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  165
• 氢给体数：
  6
• 氢受体数：
  9

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S36/37
• 危险类别码：
  R20/21/22
• WGK Germany：
  1
• 海关编码：
  2919900090

文献信息

• Method of preparing tissues for vitrification
  申请人：THE AMERICAN NATIONAL RED CROSS

  公开号：US20010031459A1

  公开（公告）日：2001-10-18

  The invention relates to the field of organ and tissue perfusion. More particularly, the present invention relates to a method for preparing organs, such as the kidney and liver, for cryopreservation through the introduction of vitrifiable concentrations of cryoprotectant into them. To prepare the organ for cryopreservation, the donor human or animal, is treated in the usual manner and may also be treated with iloprost, or other vasodilators, and/or transforming growth factor &bgr;1. Alternatively, or additionally, the organ which is to be cryopreserved can be administered iloprost, or other vasodilators, and/or transforming growth factor &bgr;1 directly into its artery. The invention also relates to preparing organs for transplantation by a method for the removal of the cryoprotectant therefrom using low (such as raffinose, sucrose, mannitol, etc.), medium (such as agents with intermediate molecular weights of around 600-2,000) and high (such as hydroxyethyl starch) molecular weight agents osmotic buffering agents. The invention is also directed to new post-transplantation treatments such as the use of transforming growth factor &bgr;1, N-acetylcysteine and aurothioglucose.

  本发明涉及器官和组织灌注领域。更具体地说，本发明涉及一种通过向器官（如肾脏和肝脏）中导入玻璃化浓度的低温保护剂来准备低温保存器官的方法。为了准备用于低温保存的器官，供体人或动物要按照通常的方式进行处理，也可以用伊洛前列素或其他血管扩张剂和/或转化生长因子&bgr;1进行处理，或者，也可以将伊洛前列素或其他血管扩张剂和/或转化生长因子&bgr;1直接注入要低温保存的器官的动脉。本发明还涉及通过使用低（如棉子糖、蔗糖、甘露醇等）、中（如分子量在 600-2000 左右的中间物质）和高（如羟乙基淀粉）分子量的渗透缓冲剂去除其中的冷冻保护剂的方法制备移植用器官。本发明还涉及新的移植后治疗方法，如使用转化生长因子&bgr;1、N-乙酰半胱氨酸和urothioglucose。
• METHODS OF PREPARING ORGANS FOR CRYOPRESERVATION AND SUBSEQUENT TRANSPLANTATION
  申请人：THE AMERICAN NATIONAL RED CROSS

  公开号：EP0777413A1

  公开（公告）日：1997-06-11
• METHOD OF CRYOPRESERVATION OF BLOOD VESSELS BY VITRIFICATION
  申请人：Organ Recovery Systems, Inc.

  公开号：EP1182926B1

  公开（公告）日：2003-12-17
• METHOD OF CRYOPRESERVATION OF TISSUES OR ORGANS OTHER THAN A BLOOD VESSEL BY VITRIFICATION
  申请人：Organ Recovery Systems, Inc.

  公开号：EP1326492A2

  公开（公告）日：2003-07-16
• Method of cryopreservation of tissues by vitrification
  申请人：Khirabadi S. Bijan

  公开号：US20050100876A1

  公开（公告）日：2005-05-12

  A method for vitrification of a tissue or organ includes immersing the tissue or organ in increasing concentrations of cryoprotectant solution at a temperature greater than −15° C. to a cryoprotectant concentration sufficient for vitrification; cooling the tissue or organ at an average rate of from 2.5-100° C. per minute to a temperature between −80° C. and the glass transition temperature; and further cooling the tissue or organ at an average rate less than 30° C. per minute to a temperature below the glass transition temperature to vitrify the tissue or organ. After the vitrified tissue or organ has been stored, the tissue or organ may be removed from vitrification by warming the tissue or organ at an average rate of from 20-40° C. per minute to a temperature between −80° C. and the glass transition temperature; further warming the tissue or organ at a rate greater than 80° C. per minute to a temperature above −75° C.; and reducing the concentration of the cryoprotectant. Tissues or organs treated in this manner exhibit near normal functions, for example, blood vessels exhibit near normal smooth muscle contractility and normal graft functions.